KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
6.20
+0.02 (0.32%)
Nov 21, 2024, 10:07 AM EST - Market open

Company Description

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.

The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.

Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA BIO, Inc.
KALA BIO logo
Country United States
Founded 2009
IPO Date Jul 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Mark Iwicki

Contact Details

Address:
1167 Massachusetts Avenue
Arlington, Massachusetts 02476
United States
Phone 781 996 5252
Website kalarx.com

Stock Details

Ticker Symbol KALA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001479419
CUSIP Number 483119103
ISIN Number US4831192020
Employer ID 27-0604595
SIC Code 2834

Key Executives

Name Position
Mark T. Iwicki Chairman and Chief Executive Officer
Todd Bazemore President and Chief Operating Officer
Dr. R. Kim Brazzell Ph.D. Head of Research & Development and Chief Medical Officer
Dr. Justin Hanes Ph.D. Founder and Chair of the Scientific Advisory Board
Mary Reumuth CPA Chief Financial Officer and Treasurer
Jill S. Steier Executive Director of Investor Relations and Corporate Communications
Vincent Kosewski Senior Vice President of Manufacturing and Supply Chain Management
Darius Kharabi J.D., M.B.A. Chief Business Officer
Dr. Francis S. Mah M.D. Chief Medical Advisor
Josiah Craver Senior Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Sep 25, 2024 8-K Current Report
Sep 6, 2024 424B5 Filing
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jul 31, 2024 EFFECT Notice of Effectiveness
Jul 31, 2024 424B3 Prospectus
Jul 26, 2024 UPLOAD Filing